Skip to content.

Aptose Biosciences Inc. closes public offering of common shares

Date Closed

July 20, 2020

Lead Office

Québec City


61.68 Million USD

On July 20, 2020, Aptose Biosciences Inc. closed its public offering of common shares, amounting to gross proceeds of approximately US$61.6 million. This was a U.S.-only offering and no shares were offered or sold in Canada.

The proceeds from this offering will be used to accelerate and expand clinical trials for Aptose's CG-806 and APTO-253 drugs as well as to acquire and fund additional clinical assets.

McCarthy Tétrault advised Aptose with a team led by Charles-Antoine Souliere and included Isabelle Nazon and Laetitia Ouedraogo.